How to Investigate and Treat: Headache and Hyperprolactinemia

Overview

Journal Curr Pain Headache Rep

Date 2012 May 29

PMID 22639180

Citations 8

Authors

Gennaro Bussone

Susanna Usai

Franca Moschiano

Affiliations

Soon will be listed here.

Abstract

Hyperprolactinemia is a condition characterised by an increase of prolactin blood levels (more than 100-200 ng/ml). It is the most common endocrine disorder of the hypothalamic-pituitary axis. The clinical characteristics of the headache-hyperprolactinemia-hypophyseal-adenoma association are discussed, the various diagnostic and treatment possibilities are explored and the etiology of the headache is considered in the light of several pathogenetic possibilities. We present two cases. (1) A 35-year-old woman suffering from chronic tension-type headache interspersed with occasional episodes of migraine without aura (as defined by the International Headache Society criteria). She had also suffered menstrual cycle alterations since the age of 16. At the age of 30 she developed amenorrhea with hyperprolactinemia. Computed tomography (CT) and magnetic resonance imaging (MRI) scans revealed a median-left intrasellar mass. Treatment with cabergoline resulted in complete resolution of both types of headache and the menstrual cycle and prolactin levels returned to normal. The therapy also reduced the volume of the tumour. (2) The second case relates to a 47-year-old man who had been suffering from tension-type headaches for almost 3 months. The patient had never previously suffered from headaches. CT and MRI scans showed a large sellar and suprasellar lesion with raised serum prolactin levels. Treatment with cabergoline had significantly reduced the prolactin levels and had also improved the patient's headaches. High-resolution CT, with and without contrast, or MRI is necessary to visualise microprolactinomas (and other sellar lesions) and confirm the diagnosis.

Citing Articles

The influence of sex on neuroimmune communication, pain, and physiology.

Alexander S, Green A, Debner E, Ramos Freitas L, Abdelhadi H, Szabo-Pardi T Biol Sex Differ. 2024; 15(1):82.

PMID: 39439003 PMC: 11494817. DOI: 10.1186/s13293-024-00660-w.

Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders.

Maciuba S, Bowden G, Stratton H, Wisniewski K, Schteingart C, Almagro J MAbs. 2023; 15(1):2254676.

PMID: 37698877 PMC: 10498814. DOI: 10.1080/19420862.2023.2254676.

Italian Guidelines for the Management of Prolactinomas.

Cozzi R, Auriemma R, De Menis E, Esposito F, Ferrante E, Iati G Endocr Metab Immune Disord Drug Targets. 2023; 23(12):1459-1479.

PMID: 37171003 PMC: 10556400. DOI: 10.2174/1871530323666230511104045.

Prolactin and oxytocin: potential targets for migraine treatment.

Szewczyk A, Ulutas S, Akturk T, Al-Hassany L, Borner C, Cernigliaro F J Headache Pain. 2023; 24(1):31.

PMID: 36967387 PMC: 10041814. DOI: 10.1186/s10194-023-01557-6.

Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Cozzi R, Ambrosio M, Attanasio R, Battista C, Bozzao A, Caputo M Eur J Endocrinol. 2022; 186(3):P1-P33.

PMID: 35000899 PMC: 8859924. DOI: 10.1530/EJE-21-0977.

References

Evans R, Levy M . Expert opinion: Headache and pituitary tumors. Headache. 2008; 48(2):280-3. DOI: 10.1111/j.1526-4610.2007.01020.x. View

Bosco D, Belfiore A, Fava A, De Rose M, Plastino M, Ceccotti C . Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. J Headache Pain. 2008; 9(2):103-7. PMC: 3476184. DOI: 10.1007/s10194-008-0016-z. View

Zidverc-Trajkovic J, Vujovic S, Sundic A, Radojicic A, Sternic N . Bilateral SUNCT-like headache in a patient with prolactinoma responsive to lamotrigine. J Headache Pain. 2009; 10(6):469-72. PMC: 3476218. DOI: 10.1007/s10194-009-0146-y. View

Scarone P, Losa M, Mortini P, Giovanelli M . Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. J Neurooncol. 2005; 76(1):51-4. DOI: 10.1007/s11060-005-2319-0. View

Eren E, Yapici S, Papatya Cakir E, Ceylan L, Saglam H, Tarim O . Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol. 2011; 3(2):65-9. PMC: 3119443. DOI: 10.4274/jcrpe.v3i2.14. View

Matharu M, Levy M, Merry R, Goadsby P . SUNCT syndrome secondary to prolactinoma. J Neurol Neurosurg Psychiatry. 2003; 74(11):1590-2. PMC: 1738244. DOI: 10.1136/jnnp.74.11.1590. View

Levy M, Matharu M, Goadsby P . Chronic headache and pituitary tumors. Curr Pain Headache Rep. 2008; 12(1):74-8. DOI: 10.1007/s11916-008-0014-5. View

Levy M . The association of pituitary tumors and headache. Curr Neurol Neurosci Rep. 2010; 11(2):164-70. DOI: 10.1007/s11910-010-0166-7. View

Nishioka H, Haraoka J, Akada K . Growth potential of prolactinomas in men: is it really different from women?. Surg Neurol. 2003; 59(5):386-90; discussion 390-1. DOI: 10.1016/s0090-3019(03)00012-0. View

10.

Hartman N, Voron S, Hershman J . Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma). Headache. 1995; 35(7):430-1. DOI: 10.1111/j.1526-4610.1995.hed3507430.x. View

11.

Ferrari C, PARACCHI A, Mattei A, De Vincentiis S, DALBERTON A, Crosignani P . Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 1992; 126(6):489-94. DOI: 10.1530/acta.0.1260489. View

12.

Zarate A, Moran C, Miranda R, Loyo M, Medina M, Fonseca M . Long-acting bromocriptine for the acute treatment of large macroprolactinomas. J Endocrinol Invest. 1987; 10(3):233-6. DOI: 10.1007/BF03348119. View

13.

Levy M, Matharu M, Meeran K, Powell M, Goadsby P . The clinical characteristics of headache in patients with pituitary tumours. Brain. 2005; 128(Pt 8):1921-30. DOI: 10.1093/brain/awh525. View

14.

Strebel P, Zacur H, Gold E . Headache, hyperprolactinemia, and prolactinomas. Obstet Gynecol. 1986; 68(2):195-9. View

15.

. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 Suppl 1:9-160. DOI: 10.1111/j.1468-2982.2003.00824.x. View

16.

Prabhakar V, Davis J . Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol. 2007; 22(2):341-53. DOI: 10.1016/j.bpobgyn.2007.08.002. View

17.

Nishioka H, Ito H, Haraoka J, Hirano A . Growth potential of female prolactinomas. Surg Neurol. 2001; 55(4):213-7. DOI: 10.1016/s0090-3019(01)00407-4. View

18.

Jimenez Caballero P . SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks. Cephalalgia. 2007; 27(1):76-8. DOI: 10.1111/j.1468-2982.2007.01229.x. View

19.

Corsello S, Ubertini G, Altomare M, Lovicu R, Migneco M, Rota C . Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003; 58(5):662-70. DOI: 10.1046/j.1365-2265.2003.01770.x. View

20.

Famini P, Maya M, Melmed S . Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011; 96(6):1633-41. PMC: 3100749. DOI: 10.1210/jc.2011-0168. View